Medical Properties Trust (MPT) Stock Looks Undervalued After Asset Sale Plans

Medical Properties Trust has seen a prolonged share price slide, and that kind of track record pushes the focus squarely onto what its current price implies about the cash the business can generate. With the stock now trading around the mid single digits, the obvious question is whether the recent valuation still lines up with the cash flows its hospitals portfolio can realistically support.

• Over the past 5 years the share price has fallen 73.6%, which puts the spotlight on whether investors are now paying an appropriate amount for the trust's future cash flows from its hospital real estate.
• The recently completed sale of two hospitals for US$371 million in cash, with plans to use most of the proceeds to reduce debt, may reshape how investors think about Medical Properties Trust's interest costs and the durability of its cash flows.
• If you'd rather focus on sales, this one's for you. See what Medical Properties Trust's 1.9x P/S says about the price.

The issue now is whether the current share price is justified by Medical Properties Trust's cash flows when viewed through an intrinsic value lens based on its Discounted Cash Flow (DCF) estimate.

If you want to put Medical Properties Trust's valuation question alongside other potential ideas, you can scan companies through the 29 high quality undervalued stocks.

Does Medical Properties Trust Look Undervalued on Cash Flow?

The Discounted Cash Flow (DCF) model here values Medical Properties Trust based on the cash it can return to equity holders over time. On the latest numbers, the trust is generating last twelve month free cash flow of about $183.9 million, using adjusted funds from operations as a proxy. Analyst projections then build in recovering free cash flows over the coming years rather than a shrinking profile, with the model using a two stage approach that tapers growth in the later period.

Because the recent DCF projections put Medical Properties Trust's estimated intrinsic value meaningfully above the current share price of $3.60, the model implies that the equity is pricing in a fair amount of caution around those future cash streams. The recently announced US$371 million cash inflow from selling two hospitals and the stated intention to use most of it to reduce debt helps explain why the cash flow outlook in the model assumes some recovery instead of ongoing pressure. This gap between the DCF estimate and the market price is where the detailed valuation work becomes useful for readers who want to test their own expectations against the model's assumptions. Find out what Medical Properties Trust could be worth using our Discounted Cash Flow (DCF) estimate.

The Medical Properties Trust Narrative: What Would Justify Today's Price?

Narratives on Simply Wall St take Medical Properties Trust's valuation puzzle a step further by spelling out the specific paths for future growth, margins and earnings that would need to play out for the stock to be worth materially more or materially less than today’s price. They live on the Community page, where a single ratio or DCF output is unpacked into the concrete future it assumes, so you can watch over time whether that picture still fits.

One of the top community narratives on Medical Properties Trust: 30% undervalued

"High tenant concentration, asset impairments, rising debt costs, regulatory uncertainties, and sector-wide pressures threaten earnings stability and cash flow..."

Discover why this Narrative puts Medical Properties Trust at 30% undervalued.

Before acting on Medical Properties Trust’s valuation, there is one more angle to check

Price and cash flow only tell part of the Medical Properties Trust story, and recent research checks have highlighted specific concerns that investors may want to review closely before moving further. Take a closer look at 3 warning signs (2 major) before settling on a valuation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com